For research use only. Not for therapeutic Use.
Crisaborole（Cat No.:I006297）is a non-steroidal topical phosphodiesterase-4 (PDE-4) inhibitor used to treat mild to moderate atopic dermatitis (eczema). By inhibiting PDE-4, Crisaborole reduces the production of inflammatory cytokines, helping to control inflammation and alleviate symptoms like itching and redness. Its non-steroidal formulation makes it a preferred option for long-term management of eczema, minimizing the risks associated with corticosteroid use. With its proven efficacy and well-tolerated safety profile, Crisaborole offers an effective treatment option for patients seeking relief from chronic skin inflammation.
| Catalog Number | I006297 |
| CAS Number | 906673-24-3 |
| Synonyms | AN2728 |
| Molecular Formula | C14H10BNO3 |
| Purity | 98% |
| Target | Phosphodiesterase (PDE) |
| Target Protein | |
| Solubility | Soluble in DMSO, not in water |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| Related CAS | (or 906673-25-4) |
| IC50 | PDE4:0.49 μM(IC50) |
| IUPAC Name | 4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile |
| InChI | InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2 |
| InChIKey | USZAGAREISWJDP-UHFFFAOYSA-N |
| SMILES | B1(C2=C(CO1)C=C(C=C2)OC3=CC=C(C=C3)C#N)O |
